Clinical implementation of AI contouring in prostate radiotherapy planning
In the UK prostate cancer is the most common cancer in men and the second most common cancer overall. One in eight men will develop prostate cancer, with over 50% of prostate cancer diagnoses in people aged 70 or above. There were 52,300 cases of prostate cancer between 2016 and 2018 and incidence rates are projected to rise by 15% between 2023 and 2040. Localised prostate cancer has many treatment options in the UK with external beam radiotherapy, brachytherapy, radical prostatectomy, active surveillance or androgen deprivation therapy being available. In 2020, 33% of patients with prostate cancer had radiotherapy as part of their primary cancer treatment.
The content on this page is provided by the individuals concerned and does not represent the views or opinions of RAD Magazine.


